Department of Breast Surgery, The Tumor Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Clin Transl Oncol. 2020 Dec;22(12):2275-2285. doi: 10.1007/s12094-020-02369-9. Epub 2020 May 23.
Patients presenting with lymphovascular space invasion (LVSI) had an absolute decrease in survival. In our present study, the potential roles of LVSI on tumor characteristics was explored to predict the difference in the prognosis of ER and HER2 positive T1 tumors.
A total of 142 breast cancer patients diagnosed with ER+ and HER2+ tumors whose tumor size was ≤ 2 cm were included in this analysis. One hundred forty-two patients were divided into four groups, group 1 (lymph nodes+ and LVSI+), group 2 (lymph nodes+ and LVSI-), group 3 (lymph nodes- and LVSI+), group 4 (lymph nodes- and LVSI-). Univariate and multivariate Cox proportional hazard models were used to identify independent prognostic factors and calculate the HR and 95% CI. Kaplan-Meier and Cox regression models were used to test the prognostic significance.
LVSI positivity was significantly associated with patient age, menopausal status, tumor size, lymph node status, Ki67, PR, and tumor grade. In the univariate and multivariate model, LVSI, PR, and Ki67 were significantly associated with DFS, and LVSI, lymph node status, PR, and Ki67 were significantly associated with OS. LVSI was significantly related to increased risk of DFS and OS only in the PR-negative and low-positive subgroups. It was a prognostic factor for DFS but not for OS in women with low Ki67 and was associated with DFS and OS in high-Ki67 tumors. Furthermore, patients who presented with only LVSI had a significantly worse survival rate than those with lymph node metastasis without LVSI in small tumors.
The presence of LVSI was highlighted as a variable significant to survival. In further clinical practice, patients with LVSI may need more intensive treatment in certain populations.
有淋巴血管空间侵犯(LVSI)表现的患者生存绝对下降。在本研究中,我们探讨了 LVSI 对肿瘤特征的潜在作用,以预测 ER 和 HER2 阳性 T1 肿瘤预后的差异。
共纳入 142 例诊断为 ER+ 和 HER2+ 肿瘤且肿瘤大小≤2cm 的乳腺癌患者进行本分析。142 例患者分为四组,组 1(淋巴结+和 LVSI+)、组 2(淋巴结+和 LVSI-)、组 3(淋巴结-和 LVSI+)、组 4(淋巴结-和 LVSI-)。采用单因素和多因素 Cox 比例风险模型识别独立预后因素,并计算 HR 和 95%CI。采用 Kaplan-Meier 和 Cox 回归模型检验预后意义。
LVSI 阳性与患者年龄、绝经状态、肿瘤大小、淋巴结状态、Ki67、PR 和肿瘤分级显著相关。在单因素和多因素模型中,LVSI、PR 和 Ki67 与 DFS 显著相关,LVSI、淋巴结状态、PR 和 Ki67 与 OS 显著相关。LVSI 仅在 PR 阴性和低阳性亚组中与 DFS 风险增加显著相关。LVSI 是 PR 阴性和 Ki67 低患者的 DFS 预后因素,但不是 OS 预后因素,与 Ki67 高的肿瘤的 DFS 和 OS 相关。此外,在小肿瘤中,仅存在 LVSI 的患者的生存率明显低于无 LVSI 的淋巴结转移患者。
LVSI 的存在被强调为与生存相关的重要变量。在进一步的临床实践中,在某些人群中,存在 LVSI 的患者可能需要更强化的治疗。